Abstract. Cancer has long been one of the most malignant diseases worldwide. Processes in cancer cells are often mediated by Jun N-terminal kinase (JNK), p38 mitogen-activated protein kinase (p38 MAPK) and other signaling pathways. Traditional therapies are often problematic. Recently, a novel polysaccharide derived from algae extract was investigated due to the increasing interest in biological activities of compounds from marine organisms. The effect of this novel polysaccharide on human MKN45 gastric carcinoma cells was determined previously. The current aimed to determine whether the polysaccharide affects other types of cancer, and the deeper mechanisms involved in the process. Human MCF-7 breast cancer cells were used to investigate the novel polysaccharide for its role in the cell growth and migration, and determine the mechanisms affected. MTT assay, nuclear staining and fluorescence activated cell sorting analysis demonstrated that the novel polysaccharide reduced the viability of MCF-7 cells by inducing cell apoptosis and arresting the cells at G2/M phase.
Introduction
Cancer has long been one of the most malignant diseases and a leading cause of mortality, worldwide (1) . In recent years, with the accelerated pace of life, the deterioration of the environment and the increased work pressures, the incidence of cancer increase year by year (2) . In the past, surgery and radiotherapy has been the most common treatment method (3) . Although there is now a new era of molecular targeted therapy, these traditional therapies often bring numerous unwanted side effects and problems, and do not always improve the symptoms (4) . Due to the limited efficacy traditional therapeutics, it is important to identify novel treatment strategies with reduced side effects.
In recent years, in Japan and worldwide, the interest in the biological activities of compounds from marine organisms is increasing (5) . Various compounds with biological activities have been investigated and several have been developed into herbal medicines that are commercially available (6) . A novel polysaccharide derived from algae extract has been previously investigated. The biological activity of this novel polysaccharide was first investigated using retinal pigment epithelial cells (7) , and the effect in inhibiting human gastric carcinoma MKN45 cells was also reported recently (8) . The current study aimed to determine if this extract affects other types of cancers, and the signaling pathways involved. Human MCF-7 breast cancer cells were used to investigate the effect of the novel polysaccharide on MCF-7 proliferation and migration, and determine the mechanisms involved in the process.
Abnormal proliferation and migration are critical physiological processes for cancer cell invasion (9) . Induction of cell apoptosis is a useful mechanism to inhibit cell proliferation (10) . In addition to apoptosis, cell cycle arrest is another cause of proliferation inhibition (11) . It is well established that mitogen-activated protein kinase (MAPK) signaling pathways are involved in cell cycle, proliferation and migration (12) . Jun N-terminal kinase (JNK), a member of MAPK A novel polysaccharide derived from algae extract inhibits cancer progression via JNK, not via the p38 MAPK signaling pathway family, is associated with cell proliferation inhibition (13) . Phosphorylation of JNK activates downstream tumor suppressors, p53, caspase-9 and caspase-3, followed by apoptosis and cell cycle arrest (14) . p38 MAPK, another member of MAPK family, increases matrix metalloproteinase-9 (MMP-9)/ MMP-2 activity and induces cell migration (15) . Based on the conclusions of our previous experiments using MKN45 cells (8) , in the current study, MCF-7 cells were used to investigate the effect of the novel polysaccharide on the development of cancer, and to understand the mechanisms involved in the processes. The novel polysaccharide derived from algae extract suppressed MCF-7 cell proliferation by inducing apoptosis and cell cycle arrest, and activating the JNK signal pathway involving p53, caspase-9 and caspase-3. By contrast, this polysaccharide did not affect migration and did not change p38 MAPK signaling and the downstream MMP-9/MMP-2.
Materials and methods
Preparation of the novel polysaccharide. The novel polysaccharide was obtained from Toyo Medicine Institute (Ashikita, Japan). The novel polysaccharide was extracted from a type of Phaeophyceae (Sargassum), which is rich in hydrion and sulfate. The structure (Fig. 1 ) of the novel polysaccharide is modified by sulfate and phosphate groups (represented by R), with a typical sugar chain made of polymeride of disaccharides. According to the method described previously (16, 17) , the novel polysaccharide was extracted using chloroform, ethyl acetate and n-butyl alcohol. Following isolation by column chromatography on silica gel and Sephadex LH-20 columns (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA), polysaccharide was purified on a macroporous absorption resin column, and then sulfonated by sulfuric acid. The molecular weight of the polysaccharide was 11680. The molecular weight was used for calculation of molar concentration (µM) (18) .
Cell culture. MCF-7 cells expressing the fluorescent ubiquitination-based cell cycle indicator (Fucci) probes (MCF-7-Fucci cells) were purchased from RIKEN BioResource Center (Tsukuba, Japan). MCF-7-Fucci cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin) (all from Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). HeLa cells (RIKEN BioResource Center) were cultured in Dulbecco's modified Eagle's medium (Sigma-Aldrich; Merck KGaA) supplemented with 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin. MCF-7 cells and HeLa cells were incubated in 5% CO 2 at 37˚C for all experiments.
MTT assay. Following pretreatment with SP600125 (5 µM) for 1 h or no treatment, MCF-7 cells or HeLa cells were plated at a density of 5x10 3 cells/well in a 96-well plate and exposed to polysaccharide (100 µg/ml) for 48 h. According to the method described by Yuan et al (19) , the viability of cells was determined by a colorimetric MTT assay. Absorbance at 550 and 690 nm was determined by an MTP-800 microplate reader (Corona Electric, Co., Ltd., Tokyo, Japan). The percentage of viable cell number was calculated as: Optical density (OD) of treated sample/OD of untreated control cells x100.
Fluorescence activated cell sorting (FACS) analysis. MCF-7 cells were incubated in a 6-well plate (1x10 5 cells/well) in RPMI medium. After treatment with the polysaccharide (100 µg/ml) for another 48 h, MCF-7 cells were washed twice with PBS (Sigma-Aldrich; Merck KGaA). To detect the apoptosis of cell, 10,000 individual cells were collected for each sample and Annexin V-Biotin Apoptosis kit was used following the manufacturer's instructions (BioVision, Inc., Milpitas, CA, USA). Apoptotic cells were analyzed using a FACSCalibur™ flow cytometer (BD Biosciences, San Jose, CA, USA) with CellQuest software (version 6.1; BD Biosciences).
Cell cycle analysis. Cell cycle analysis was performed by flow cytometry using a FACSCalibur™ and CellQuest software, as previously described (20) . Briefly, MCF-7 cells (1x10 5 cells/well) were exposed to polysaccharide (100 µg/ml) for 48 h, washed and re-suspended in PBS (420 µl) following trypsinization and fixed in 99% ethanol at -20˚C for 2 h. Subsequently, samples were incubated in 50 µl 10 mg/ml RNase A (Sigma-Aldrich; Merck KGaA) at 37˚C for 30 min, and then incubated with propidium iodide (20 µl 0.2 mg/ml solution) at room temperature for another 10 min. Subsequently, DNA content was evaluated by FACS.
Nuclear staining. MCF-7 cells or HeLa cells were cultured in 6-well plates (1x10 5 cells/well) for 24 h. Following treatment with the polysaccharide (100 µg/ml) for another 48 h, cells were washed with PBS, and fixed in 4% paraformaldehyde (Sigma-Aldrich; Merck KGaA) for 30 min. Cells were stained with Hoechst 33342 (20 mg/ml) at room temperature in the dark for 15 min. Then cell morphological changes were assessed by fluorescence microscopy.
Fucci system. MCF-7 cells were plated at a density of 1x10 5 cells/well in a 6-well plate and treated with polysaccharide (100 µg/ml) for 48 h. The MCF-7 cells used expressed two Fucci probes, emitting red fluorescence (SCF Skp2 ) in G1/G0 phase and green fluorescence (APC Cdh1 ) in S/G2/M phases (21) . A FV10i-DOC confocal laser-scanning microscope with a UPLSAPO x60 Wobjective lens (Olympus Corporation, Tokyo, Japan) was used to observe the cellular fluorescence and obtain phase contrast images as previously described (22) .
Migration assay. A 48-well chamber migration assay kit with polycarbonate membrane (Whatman ® Nuclepore™; Sigma-Aldrich; Merck KGaA) was used for a migration assay according to the method previously described (23) . Briefly, the upper wells were coated with 0.01% collagen for 30 min at 37˚C. MCF-7 cells were treated with polysaccharide (100 µg/ml) for 48 h at 37˚C, then MCF-7 cells (5x10 4 cells/well) were seeded on the upper chamber of the Transwell in serum-free RPMI medium. As chemotactic medium, RPMI containing 10% fetal calf serum (Sigma-Aldrich; Merck KGaA) was added to the lower wells. After 24 h at 37˚C, the cells that migrated towards to the lower filter surface were fixed with 4% paraformaldehyde for 10 min at room temperature and then stained with crystal violet for 10 min at room temperature. The number of migrated cells was counted under a x100 microscope (Olympus Optical, Co., Ltd., Tokyo, Japan).
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)
. MCF-7 cells were treated with TRIzol reagent (Life Technologies; Thermo Fisher Scientific, Inc.) for 2-3 min to completely dissolve cells. Total RNA was extracted from MCF-7 cells. RT was performed using a Transcriptor First Strand cDNA Synthesis kit (Roche Applied Science, Madison, WI, USA), with incubation at 37˚C for 20 min, then 75˚C for 10 min. The relative mRNA quantification was performed by ABI 7300 Fast real-time PCR system (Applied Biosystems, Foster City, CA, USA) and normalized to GAPDH. SYBR Premix Ex Taq II (Takara Bio, Inc., Otsu, Japan) was used and the thermocycling conditions were: 95˚C for 30 sec for pre-denaturation, then 40 cycles of 95˚C for 3 sec for denaturation, 60˚C for 31 sec for annealing and 72˚C for 60 sec for elongation, and finally 72˚C for 5 min for re-elongation. RT-qPCR results were analyzed by 2 -ΔΔCq method described by Livak and Schmittgen (24) . Certified™ PCR Agarose (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and ethidium bromide (Sigma-Aldrich; Merck KGaA) staining were used to separate PCR products. The following primers (Hokkaido System Science Co., Ltd., Sapporo, Japan) were used: MMP-9, forward, 5'-CTTCACTTTCCTGGGTAAG-3' and reverse, 5'-CACTTCTTGTCGCTGTCAAA-3'; MMP-2, forward, 5'-GACATACATCTTTGCTGGAGAC-3' and reverse, 5'-TTCAGGTAATAGGCACCCTT-3'; and GAPDH, forward, 5'-TGCACCACCAACTGCTTAGC-3' and reverse, 5'-GGCATG GACTGTGGTCATGAG-3' .
Gelatin zymography. MCF-7 cells (1x10 5 cells/well) were pretreated with 100 µg/ml polysaccharide in RPMI medium for 48 h. As described previously (25) , supernatants of culture medium of MCF-7 cells (10 µl) were collected and subjected to electrophoresis (10% SDS-polyacrylamide gel copolymerized with 0.1% gelatin for substrate reaction). After washing in 2.5% Triton X-100 to remove SDS, gels were then incubated with developing buffer (50 mM Tris-HCl pH 7.4, 200 mM NaCl, 5 mM CaCl 2 and 0.02% Briji-35) at 37˚C for >12 h. Gels were then stained with 0.5% Coomassie Brilliant Blue R-250 for 2 min for band observation. The intensities of bands were quantified with ImageJ software (National Institutes of Health, Bethesda, MA, USA). The sum of MMP-9 and MMP-2 bands was determined as activity.
Western blot analysis. The western blot analysis was performed as described previously (26) . Proteins were extracted using lysis buffer (1 M Tris-HCl, pH 7.4; 1 M NaCl; 20% Triton X100; 10% SDS; and 0.5 M EDTA). Protein concentration was determined by bicinchoninic acid method as described previously (27) . A total of 20 µg protein was loaded per lane of a 12% polyacrylamide gel. The polyvinylidene fluoride membrane (Thermo Fisher Scientific, Inc., Waltham, MA, USA) was treated with Block Ace™ (4%) for 30 min at 22˚C. The first reaction was performed using rabbit immunoglobulin (Ig)G antibodies against JNK (cat. no. J4500; 1:2,000), phospho-JNK (cat. no. 07-175; 2 µg/ml), p53 (cat. no. SAB4503015; 1:500), caspase-9 (cat. no. C7729; 1:300), caspase-3 (cat. no. C9598; 1:3,000) and p38 MAPK (cat. no. SAB4500492; 1:500) (all from Sigma-Aldrich; Merck KGaA) in PBS containing 0.03% Tween-20 for 1 h at room temperature. Following washing in the same buffer three times, the second reaction was performed using horseradish peroxidase-conjugated anti-rabbit goat IgG (cat. no. A0545; 20 ng/ml; Sigma-Aldrich; Merck KGaA) for 30 min at room temperature. Following washing, enhanced chemiluminescence (ECL) was used to incubate the membrane and visualized using the ECL Plus Western Blotting Detection System™ (GE Healthcare Life Sciences, Little Chalfont, UK). ImageJ (version 1.49v; National Institutes of Health, Bethesda, MD, USA) was used for the densitometry analysis of western blots.
Detection of intracellular reactive oxygen species (ROS).
Intracellular accumulation of ROS was estimated using the fluorescent dye H2-dichlorofluorescin diacetate (DCFDA; Life Technologies; Thermo Fisher Scientific, Inc.), which is converted to a membrane impermeable and highly fluorescent compound, dichlorofluorescin (DCF), in the presence of ROS. The MCF-7 cells were seeded in a 6-well plate at the density of 1x10 5 cells/well. Following treatment with the polysaccharide (100 µg/ml) or SP600125 (5 µM), MCF-7 cells (1x10 5 cells/well) were further incubated for 48 h. The cells were rinsed with serum-free medium and were incubated in 5 µM H2-DCFDA for 60 min at 37˚C. The cells were then examined under a fluorescence microscope (C1-T-SM; Nikon Corporation, Tokyo, Japan), collected and subjected to a fluorescence spectrophotometry (F-2500; Hitachi, Ltd., Tokyo, Japan) to detect the DCF fluorescence inside cells (excitation, 488 nm; emission, 521 nm) as described (8) .
Statistical analysis. Analyses were performed using SPSS 19.0 (IBM Corp., Armonk, NY, USA). All data were presented as the mean ± standard deviation of three independent experiments. Normality of distribution was analyzed by D' Agostino and Pearson omnibus normality test. Multiple comparisons between groups were performed using one-way analysis of variance and post hoc test (Dunnett's test). P<0.05 was considered to indicate a statistically significant difference.
Results
Novel polysaccharide suppresses cell proliferation, induces cell apoptosis and cell cycle arrest in MCF-7 cells. Recently, we reported that the polysaccharide inhibited the invasion ability of human MKN45 gastric carcinoma cells (8) . To better understand whether the polysaccharide has similar efficacy on other types of cancer cells, the viability of human MCF-7 breast cancer cells was determined. MCF-7 cells were exposed to 100 µg/ml polysaccharide for 48 h and the cellular viability measured by colorimetric MTT assay. The viability of MCF-7 cells was reduced by the polysaccharide treatment ( Fig. 2A) . As the inhibition of viability is typically caused by increased cellular apoptosis, FACSCalibur™ flow cytometry and nuclear staining were performed to determine cell apoptosis. The polysaccharide induced cell apoptosis compared with the cells without polysaccharide treatment (Fig. 2B and C) . Considering that the suppressed cell growth may be due to the cell cycle arrest, flow cytometry and a Fucci system were used to analyze the cell cycle. The polysaccharide arrested the cell cycle at G2/M (Fig. 3) . These results indicate that the novel polysaccharide reduced MCF-7 cells viability, and induces apoptosis and cell cycle arrest, which are consistent with the results in our previous study (8) .
Lack of inhibitory effects of the novel polysaccharide on migration or MMP-9/MMP-2 expression in MCF-7 cells.
Migratory capacity is another characteristic of cancer cells. In order to understand whether the polysaccharide affects MCF-7 cells by inhibiting cell migration, we used a migration assay kit to determine the cell migration. There was no difference in the number migrated cells between the polysaccharidetreated and non-treated MCF-7 cells (Fig. 4A) . Furthermore, the MMP-9/MMP-2 mRNA expression was measured, which was reported to be important for the migration of cancer cells. MMP-9/MMP2 mRNA expression (Fig. 4B and C) and the MMP activity (Fig. 4D) were not changed in polysaccharidetreated MCF-7 cells compared with control cells. These results suggested that the polysaccharide does not affect the migration of MCF-7 cells.
Novel polysaccharide induces the phosphorylation of JNK, and expression of p53, caspase-9 and caspase-3, with no effect on p38 MAPK phosphorylation in MCF-7 cells.
The results of the current study demonstrated that the polysaccharide inhibited MCF-7 cell viability, induced cell apoptosis and cell cycle arrest, without affecting the migration of MCF-7 cells. To further determine the potential signaling pathways involved in this process, western blot analysis was performed to detect the phosphorylation of JNK and p38 MAPK, and expression of p53, caspase-9 and caspase-3. The novel polysaccharide upregulated the phosphorylation of JNK, and the expression of p53, caspase-9 and caspase-3 (P<0.01), however, there was no effect on p38 MAPK phosphorylation in MCF-7 cells (Fig. 5A and B) . These results indicate that, the novel polysaccharide inhibits MCF-7 cell viability, and induces cell apoptosis and cell cycle arrest via JNK signaling, whereas there was no effect on cancer cell or p38 MAPK phosphorylation. 
SP600125 inhibits the effects of the novel polysaccharide on cell viability, apoptosis and cell cycle arrest in MCF-7 cells.
In order to establish whether JNK signaling pathway is necessary for this process, MCF-7 cells were pretreated with SP600125, an inhibitor of JNK (5 µM) for 1 h. Notably, SP600125 significantly blocked the polysaccharide-induced reduction in cell viability ( Fig. 2A) and prevented polysaccharide induced cell apoptosis (Fig. 2C ) and cell cycle arrest ( Fig. 3B; P<0 .01).
SP600125 prevents the novel polysaccharide-induced p53, caspase-9 and caspase-3 in MCF-7 cells.
To further clarify whether JNK signaling is necessary in the potential processes induced by the polysaccharide, cells were treated with SP600125 prior to western blot analysis of various proteins. SP600125 significantly prevented the polysaccharide-induced expression of p53, caspase-9 and caspase-3 in MCF-7 cells ( Fig. 5A and C; P<0.05) . These results were consistent with our previous finding (8) and indicated that JNK signaling is crucial and necessary in this process.
SP600125 does not affect the novel polysaccharide-induced ROS generation in MCF-7 cells. Previously, MKN45 cells were used to investigate the mechanisms of JNK/ROS (8).
As the activation of JNK is associated with ROS generation, ROS generation was analyzed in MCF-7 cells in the current study. MCF-7 cells were pretreated with 5 μM SP600125 (a JNK inhibitor) for 1 h prior to the polysaccharide (100 µg/ml) treatment. Subsequently, the cells were incubated further for 48 h. Intracellular accumulation of ROS was estimated using the fluorescent dye H2-DCFDA and flow cytometry. The novel polysaccharide significantly induced ROS generation in MCF-7 cells (Fig. 5D; P<0.01) . However, pretreatment with SP600125 did not affect the polysaccharide-induced ROS generation in MCF-7 cells, suggesting that the effects on ROS are upstream of JNK.
SP600125 prevents the novel polysaccharide-induced cell proliferation and apoptosis in human cervical cancer cell line (HeLa cells).
The biological activity of the novel polysaccharide Figure 4 . The novel polysaccharide does not alter migration or MMP-9/MMP-2 mRNA expression in MCF-7 cells. MCF-7 cells were treated with 100 µg/ml polysaccharide for 48 h. (A) Cell migration was determined using a migration assay kit, cells were stained with crystal violet. The novel polysaccharide didn't affect the migration of MCF-7 cells. Magnification, x400. MMP-9/MMP-2 mRNA expression was analysis by (B) reverse transcription-quantitative polymerase chain reaction and (C) PCR products were observed on an agarose gel. (D) MMP-9/MMP-2 activity was determined by gelatin zymography. There was no change in MMP-9/MMP-2 mRNA expression or MMP-9/MMP-2 activity in the polysaccharide-treated MCF-7 cells. Data are expressed as the mean ± standard deviation (n=3). MMP, matrix metalloproteinase.
in HeLa cells was also investigated. The novel polysaccharide inhibited cell viability and induced cell apoptosis in HeLa cells. SP600125 significantly prevented the cell viability inhibition and cell apoptosis induction by the polysaccharide. (Fig. 6; P<0 .01).
Discussion
Cancer is a major cause of mortality globally (28) . Surgery and radiotherapy are the most common therapies (2); however, due to the accompanied side-effects (1, 29) , it is necessary and crucial to develop novel treatment strategies for cancer with reduced side-effects. In recent years, research has focused on molecular-targeted treatment for cancers (30) and the interest in biological activities of compounds from marine organisms has intensified (6). Numerous compounds have been investigated, and some have been developed into herbal medicine in Japan and elsewhere (6) . A novel polysaccharide derived from algae extract was investigated in this study. The biological activity of this compound on human MKN45 gastric carcinoma cells via activating ROS/JNK signaling pathway was reported previously (8) , and in the current study, another type of human cancer cell was used, human MCF-7 breast cancer cells, to investigate the polysaccharide for anticancer activity and the mechanisms involved. As described in our previous study (8) , the effect of this novel polysaccharide in inhibiting human gastric carcinoma MKN45 cells was measured in preexperiments, where the effects were dose-dependent (1, 10, 100 and 1,000 µg/ml) and time-dependent (12, 24 and 48 h). A significant difference was reached at 100 µg/ml and at 48 h. Thus, 100 µg/ml of polysaccharide and 48 h of treatment was used in the current study.
Abnormal proliferation and migration have important physiological roles in the process of cancer invasion (8). Apoptosis and programmed cell death are crucial mechanisms of proliferation inhibition (10) . The majority of chemotherapeutic agents inhibit cancer development by inducing the mechanisms of apoptosis and programmed cell death (31) .
In accordance with the conclusions of previous experiments using MKN45 cells (8) , the present study demonstrated that the novel polysaccharide reduced cell viability and induced apoptosis in MCF-7 cells. In addition to apoptosis, cell cycle arrest is another cause of proliferation inhibition (11) . Various anticancer drugs inhibit cell cycle progression at the G0/G1, S or G2/M phases (32) . Abnormal cell cycle regulation has been linked with cancer progression, and cell cycle arrest is an effective method to block cancer cell proliferation (33, 34) . Various anticancer drugs synchronize tumor cells in M phase, which is the most radiosensitive stage of the cell cycle (35) , appropriate timing of administration results in optimal radiosensitization (36) . With the use of the Fucci system in the present study confirmed that the novel polysaccharide arrested MCF-7 cells at G2/M phase. These results again demonstrated the potential ability of the novel polysaccharide in blocking the development of cancers. The development to cancer is often associated with JNK, p38 MAPK and other signaling pathways. The MAPK family includes extracellular signal-regulated kinase (ERK), p38, JNK and ERK5 (37) . MAPK signaling pathways are the most widespread mechanisms of eukaryotic cell regulation (38) , including cell cycle, proliferation and migration regulation (12) . JNK, an important member of MAPK family, is reported to be associated with cell proliferation inhibition (13) . The activated phospho-JNK induces the expression of downstream tumor suppressors (14) . p53, a tumor suppressor, is involved in coordinating apoptosis to preserve genomic stability and prevent tumor formation. Previous studies have also suggested the involvement of p53 in the autophagic pathway (39) . p53 induces cell cycle arrest and leads to selfmediated apoptosis (40) . In addition, p53 also induces the expression of several factors involved in apoptosis, including caspase-9 and caspase-3 (41) . The activation of caspase-9 and caspase-3 induces proteolysis and leads to the damage of cell structure and functional disorder (42) . Phosphorylated JNK activates p53, caspase-9 and caspase-3, consequently leading to apoptosis and cell cycle arrest (14) . The current study demonstrated that the novel polysaccharide induced the phosphorylation of JNK, and increased the expression of p53, caspase-9 and caspase-3, suggesting the involvement of JNK activation, and p53, caspase-9 and caspase-3 expression in the inhibitory effects of the novel polysaccharide.
p38 MAPK is another member of the MAPK family. p38 MAPK signaling is the main pathway involved in inducing cell migration (43) . Notably, in the current study, the novel polysaccharide did not affect the migration of MCF-7 cells. MMP-9 and MMP-2 are key enzymes involved in tumor metastasis (44) . p38 MAPK signaling increases the activity of MMP-9 and MMP-2 and induces cell migration (15) . To better understand whether the p38 MAPK signaling pathway is involved in the effects of the polysaccharide, the expression of p38 MAPK, MMP-9 and MMP-2 were examined in the present study. The polysaccharide did not affect the mRNA expression or activity of MMP-9 and MMP-2, or the phosphorylation of p38 MAPK. These results suggested that the p38 MAPK signaling pathway and its downstream cascades were not involved in the inhibitory effects of the algae polysaccharide.
To understand the role of JNK in the effects of the novel polysaccharide, the JNK inhibitor SP600125 was used in further experiments. SP600125 significantly blocked the reduced MCF-7 cell viability cause by the novel polysaccharide, prevented the induction of cell apoptosis and cell cycle arrest. Additionally, SP600125 prevented the novel polysaccharide-induced expression of p53, caspase-9 and caspase-3 in MCF-7 cells. The association between activation JNK and ROS generation was reported in our previous study (8) ; thus, in the current study, the, generation of ROS was determined in MCF-7 cells. The novel polysaccharide significantly induced ROS generation in MCF-7 cells; however, pretreatment with SP600125 did not affect the polysaccharide-induced ROS generation in MCF-7 cells, suggesting that the effect on ROS is upstream of JNK.
Currently, three types of cancer cells have been used to investigate the biological activities of the novel polysaccharide. MKN45 cells were used in our previous study (8) and MCF-7 cells were used in the current study. In order to support the findings, experiments were also performed in HeLa cells, with the novel polysaccharide exerting similar effects on cell viability and cell apoptosis. SP600125 significantly inhibited the reduced cell viability and increased cell apoptosis induced by the polysaccharide.
A proposed pathway summary is presented in Fig. 7 . The novel polysaccharide derived from algae extract upregulates the phosphorylation of JNK, activates the downstream cascades of p53, caspase-9 and caspase-3, and the leads to the inhibition of cancer cell growth, and induces cell apoptosis and cell cycle arrest. By contrast, the polysaccharide did not alter cancer cell migration, which is typically mediated through p38 MAPK signaling pathway or MMP-9/MMP-2 downstream.
The findings of the current study demonstrated that the novel polysaccharide suppressed cancer cell proliferation, induced cancer cell apoptosis and arrested the cell cycle via JNK signaling, whereas cancer cell migration was not inhibited and there was no effect on p38 MAPK signaling pathway. The application of the polysaccharide derived from algae extract may provide a key insight into the development of novel clinical treatment for cancers with reduced side-effects. However, in addition to JNK and p38 MAPK, many signaling pathways are involved in the processes of cancer development; the deeper and more complicated mechanisms will be examined in further investigations.
